New triple therapy aims to shrink abdominal tumors in colorectal cancer

This phase 2 trial is testing whether adding PET-guided radiation and an immunotherapy drug called cadonilimab to standard chemotherapy can shrink tumors better than chemotherapy alone in people with colorectal cancer that has spread to the lining of the abdomen. The study will enroll 40 adults whose cancer progressed after first-line treatment. Participants will be randomly assigned to receive either the combination therapy or standard second-line chemotherapy.